SEC Form 4 · accession 0001144204-15-041689
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luciano Adorini
Officer — Chief Scientific Officer
Period of report
Jul 6, 2015
Accepted (ET)
Jul 8, 2015 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2015 | M | 67 | $8.6667 | A | 10,776 | D | |
| Common Stock | Jul 6, 2015 | M | 4,000 | $21.50 | A | 14,776 | D | |
| Common StockF4 | Jul 6, 2015 | S | 600 | $2,538.0246 | D | 14,176 | D | |
| Common StockF5 | Jul 6, 2015 | S | 367 | $238.6372 | D | 13,809 | D | |
| Common StockF6 | Jul 6, 2015 | S | 1,200 | $240.627 | D | 12,609 | D | |
| Common StockF7 | Jul 6, 2015 | S | 1,000 | $241.571 | D | 11,609 | D | |
| Common StockF8 | Jul 6, 2015 | S | 770 | $241.81 | D | 10,839 | D | |
| Common Stock | Jul 6, 2015 | S | 130 | $243.69 | D | 10,709 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $8.6667 | Jul 6, 2015 | M | 67 | D | — | Oct 13, 2021 | Common Stock | 67 | 0 | D |
| Option to Purchase Common StockF3 | $21.50 | Jul 6, 2015 | M | 4,000 | D | — | Nov 16, 2022 | Common Stock | 4,000 | 2,923 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on March 9, 2015.
- F2All the shares underlying this option have fully vested.
- F3The remaining shares underlying this option vest on a pro rata monthly basis through January 1, 2016, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
- F4This transaction was executed in multiple trades at prices ranging from $237.52 to $238.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $238.55 to $238.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $240.00 to $240.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $241.0150 to $242.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8This transaction was executed in multiple trades at prices ranging from $242.3200 to $242.9600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.